WO1987001282A3 - Method and composition for providing sustained opioid antagonism - Google Patents

Method and composition for providing sustained opioid antagonism Download PDF

Info

Publication number
WO1987001282A3
WO1987001282A3 PCT/US1986/001847 US8601847W WO8701282A3 WO 1987001282 A3 WO1987001282 A3 WO 1987001282A3 US 8601847 W US8601847 W US 8601847W WO 8701282 A3 WO8701282 A3 WO 8701282A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
providing sustained
opioid antagonism
antagonism
sustained opioid
Prior art date
Application number
PCT/US1986/001847
Other languages
French (fr)
Other versions
WO1987001282A2 (en
Inventor
Ronald R Tuttle
John Howes
Original Assignee
Key Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Pharma filed Critical Key Pharma
Priority to DE8686906052T priority Critical patent/DE3687575T2/en
Priority to AT86906052T priority patent/ATE84717T1/en
Publication of WO1987001282A2 publication Critical patent/WO1987001282A2/en
Publication of WO1987001282A3 publication Critical patent/WO1987001282A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prolonged opioid antagonism is provided by injection of the compound 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphine. Such injection is useful for a variety of remedial and prophylactic uses. An injectable dosage form of the compound 6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphine can be provided in a kit form with instructions as to use.
PCT/US1986/001847 1985-09-06 1986-09-08 Method and composition for providing sustained opioid antagonism WO1987001282A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE8686906052T DE3687575T2 (en) 1985-09-06 1986-09-08 USE OF 6-METHYLENE-6-DESOXY-N-CYCLOPROPYLMETHYL-14-HYDROXYDIHYDRONORMORPHINE.
AT86906052T ATE84717T1 (en) 1985-09-06 1986-09-08 USING 6-METHYLENE-6-DESOXY-NUS850906

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77321385A 1985-09-06 1985-09-06
US773,213 1985-09-06

Publications (2)

Publication Number Publication Date
WO1987001282A2 WO1987001282A2 (en) 1987-03-12
WO1987001282A3 true WO1987001282A3 (en) 1987-08-13

Family

ID=25097554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/001847 WO1987001282A2 (en) 1985-09-06 1986-09-08 Method and composition for providing sustained opioid antagonism

Country Status (5)

Country Link
EP (1) EP0236477B1 (en)
JP (1) JPS63500799A (en)
AT (1) ATE84717T1 (en)
DE (2) DE3687575T2 (en)
WO (1) WO1987001282A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232417D1 (en) 2001-08-06 2009-07-02 Euro Celtique Sa OPIOID AGONIST FORMULATIONS WITH FREEZER AND SEQUESTRATED ANTAGONIST
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
KR101486228B1 (en) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB769517A (en) * 1953-10-20 1957-03-06 Merck & Co Inc Analgesic compositions
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
FR2160957A1 (en) * 1971-11-26 1973-07-06 Fishman Jack
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
EP0144243A1 (en) * 1983-12-06 1985-06-12 Reckitt And Colman Products Limited Analgesic compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4567185A (en) * 1983-05-13 1986-01-28 Key Pharmaceuticals, Inc. Endorphin blockage
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB769517A (en) * 1953-10-20 1957-03-06 Merck & Co Inc Analgesic compositions
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
FR2160957A1 (en) * 1971-11-26 1973-07-06 Fishman Jack
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
EP0144243A1 (en) * 1983-12-06 1985-06-12 Reckitt And Colman Products Limited Analgesic compositions

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Anesthesiology, Volume 64, No. 2, February 1986, T.J. GAL M.D. et al.: "Prolonged Antagonism of Opioid Action with Intravenous Nalmefene in Man", pages 175-180, see the whole document *
CHEMICAL ABSTRACTS, Volume 103, No. 23, 9 December 1985, (Columbus, Ohio, US), M.E. MICHEL et al.: "Binding of a new Opiate Antagonist, Nalmefene, to Rat Brain Membranes", see page 61, Abstract 189569b, Methods Find. Exp. Clin. Pharmacol. 1985, 7(4), 175-7 *
CHEMICAL ABSTRACTS, Volume 88, No. 1, 2 January 1978, (Columbus, Ohio, US), E.S. VIZI et al.: "Agonist-Antagonist Interaction Studies with Morphine, 6-Azidomorphine and Oxymorphone Derivatives", see page 167, Abstract 167b, Congr. Hung. Pharmacol. Soc. (Proc.) 1974 (Pub. 1976), 2(1, Symp. Analg.), 85-96 *
Clin. Pharmacol. Ther., Volume 39, No. 1, January 1986, R. DIXON et al.: "Nalmefene: Intravenous Safety and Kinetics of a new Opioid Antagonist", pages 49-53, see the whole document *
Clin. Pharmacol. Ther., Volume 40, No. 5, November 1986, T.J. GAL, M.D. et al.: "Prolonged Blockade of Opioid Effect with Oral Nalmefene", pages 537-542, see the whole document *
Fed. Proceed. Volume 43, No. 4, 1984, C.B. MASH et al.: "Studies on Nalmefene, an Opioid Antagonist", page 967, Abstract 3987, see Abstract *
Goodman and Gilman's The Pharmacological Basis of Therapeutics", 7the edition 1985, Macmillan Publishing Company, (New York, US), pages 524-527 and 573-574, see pages 524-527 and 573-574 *
Journal Clin. Pharmacol., Volume 26, No. 7, September/October 1986, L.C.R. MOORE et al.: "Antagonism of Fentanyl-Induced Respiratory Depression with Nalmefene, page 558, see Abstract *
Journal of Medical Chemistry, Volume 18, No. 3, 1975 (US) E.F. HAHN et al.: "Narcotic Antagonists. 4. Carbon-6 Derivatives of N-Substituded Noroxymorphones as Narcotic Antagonists", pages 259-262, see page 259, left-hand column; page 260, right-hand column, lines 10-12; page 262, note (18) *
Journal of Pharmaceutical Sciences, Volume 73, No. 11, November 1984, (US), R. DIXON et al.: "Nalmefene: Radioimmunoassay for a new Opioid Antagonist" pages 1645-1646, see page 1646, figure 1 and right-hand column, lines 39-43 *
Research Communications in Chemical Pathology and Pharmacology, Volume 42, No. 3, December 1983, (US) J. HSIAO et al.: "Nalmefene: Quantitation of a new Narcotic Antagonist in Human Plasma using High Performance-Liquid Chromatography with Electrochemical Detection", pages 449-454, see pages 449-450 cited in the application *
Research Coomunications in Chemical Pathology and Pharmacology", Volume 13, No. 4, April 1976, (New York, US), R.D. HEILMAN et al.: "An Evalution of the Hot Plate Technique to Study Narcotic Antagonists", pages 635-647, see the whole document *
Substance and Alcohol Actions/Misuse, Volume 5, No. 2, 1984, Pergamon Press Ltd. (US), M.J. KATOVICH et al.: "A Rapid, Quantitative in Vivo Assay for Narcotic Antagonist", pages 87-95, see page 87 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone

Also Published As

Publication number Publication date
DE3690457T1 (en) 1987-08-06
DE3687575T2 (en) 1993-07-01
JPS63500799A (en) 1988-03-24
WO1987001282A2 (en) 1987-03-12
EP0236477A1 (en) 1987-09-16
EP0236477B1 (en) 1993-01-20
DE3687575D1 (en) 1993-03-04
ATE84717T1 (en) 1993-02-15

Similar Documents

Publication Publication Date Title
WO1987001282A3 (en) Method and composition for providing sustained opioid antagonism
AU7636287A (en) Improvements relating to the injection of fuel to an engine
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
ES8800272A1 (en) Polypeptide, a process for preparing the same, a pharmaceutical composition containing said polypeptide as well as the use thereof.
AU582047B2 (en) Composition and method to inhibit the growth of organisms by the use of bis-biguanido hexanes and essential oil mixture combinations
TW360544B (en) Analgestic and antiinflammatory fomentation pharmaceutical composition
ES8704730A1 (en) Combination of flupirtin with spasmolytics having an anticholinergic effect.
DE3066887D1 (en) Analgesic composition
ATE181353T1 (en) FUEL MIXTURES
MX9700245A (en) Novel chemical compound, its preparation and use as a drug.
CA2018229A1 (en) Carboplatin composition
PL311121A1 (en) Cinerary urn and method of making same
DE2963793D1 (en) Analgesic composition
JPS6434965A (en) Novel aconitine based compound and analgesic and antiphlogistic agent containing said compound as active ingredient
ES8107222A1 (en) 17-Cycloalkylmethyl-6-methylene-morphinane-derivatives.
ES8306593A1 (en) Compositions for topical use containing Ergot or Vinca Rosea alkaloids for treatment of hyperseborrhoea, and their preparation.
EP0034721A3 (en) Polypeptide and its production and use
LV10289A (en) New pentapeptide ta retardation composition for inhibition of dog growth inhibition tolerance
JPS5295674A (en) Preparation of 4#-substituted-2-methyl-2-piperidinopropiophenone and i ts salts
IE44403L (en) CIS-4a-PHENYL-ISOQUINOLINES
EP0274219A3 (en) Interleukin-2-containing liposome composition and method for the production thereof
JPS5212097A (en) Corner abutment and method of manufacturing the same
JPS5213937A (en) Mahjong tile and its manufacturing method
GB1496915A (en) Sealed coolant circuit with a coolant therein
JPS5522622A (en) Preparation of epoxyterpene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): DE JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986906052

Country of ref document: EP

RET De translation (de og part 6b)

Ref document number: 3690457

Country of ref document: DE

Date of ref document: 19870806

WWE Wipo information: entry into national phase

Ref document number: 3690457

Country of ref document: DE

AK Designated states

Kind code of ref document: A3

Designated state(s): DE JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1986906052

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1986906052

Country of ref document: EP